TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock. The public offering price, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant is $1.15. All of the securities in the offering were sold by the TFF Pharmaceuticals, Inc. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 15% of the number of shares and warrants offered at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Tuesday, November 22, 2022.

TFF Pharmaceuticals intends to use the net proceeds from the offering for clinical trials, research and development, working capital and general corporate purposes.

JonesTrading Institutional Services LLC acted as the sole book-running manager and Newbridge Securities Corporation acted as lead manager for the offering.


TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability.